An Open-label, Parallel-group, Single Center, Single Oral Dose Trial to Investigate the Pharmacokinetics (PK) of 50 mg Safinamide in Subjects With Moderate and Severe Renal Impairment Compared to Matched Subjects With Normal Renal Function

Trial Profile

An Open-label, Parallel-group, Single Center, Single Oral Dose Trial to Investigate the Pharmacokinetics (PK) of 50 mg Safinamide in Subjects With Moderate and Severe Renal Impairment Compared to Matched Subjects With Normal Renal Function

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Safinamide (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Merck KGaA; Newron Pharmaceuticals
  • Most Recent Events

    • 28 Mar 2013 Company changed from Merck KGaA to Newron Pharmaceuticals as reported by ClinicalTrials.gov.
    • 28 Mar 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 07 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top